BYOOVIZ DEMONSTRATED A
COMPARABLE SAFETY PROFILE
TO LUCENTIS^1,2

Summary of All Adverse Events up to Week 52
(Safety Set)²*

TEAEs

Serious ocular AE in the study eye (by preferred item)

Serious nonocular AE (occurrence ≥0.5% in either treatment group; by preferred item)

AESI^†

TEAEs leading to IP discontinuation

Deaths

•  
• Adapted from Bressler NM, et al., 2021.

•  
• Percentages are based on the number of participants in the safety set.

• ^*
• Included participants receiving at least one dose during the study period after randomization.

• ^†
• The most frequently reported adverse events of special interest were intraocular pressure increase (BYOOVIZ: 0.3%, n=1; Lucentis: 1.7%, n=6) and iridocyclitis (BYOOVIZ: 0.9%, n=3; Lucentis: 0%, n=0).

• ^‡
• PK data were obtained in 54 patients and have limitations in their interpretation. Absorption of intravitreal injection anti-VEGF product into systemic circulation is very limited.

•  
• AE=adverse event; AESI=adverse event of special interest; SAE=serious adverse event; TEAE=treatment-emergent adverse event; VEGF=vascular endothelial growth factor.